New shot could tame painful skin condition

NCT ID NCT06326476

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests siplizumab, a drug given as a shot under the skin, in 12 adults with moderate-to-severe hidradenitis suppurativa (painful boils) that hasn't improved with standard treatments. The main goal is to see if the drug safely reduces the number of inflamed lesions over 12 weeks. It's an open-label study, meaning everyone knows they're getting the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
siplizumab (a drug given as a shot under the skin)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat hidradenitis suppurativa.
What could go wrong
This is a very early, small trial with only 12 people, so results may not apply to everyone. The drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Alabama at Birmingham

    RECRUITING

    Birmingham, Alabama, 35233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.